Composition of a therapeutic oligomer
OwnerPrashant Nagpalinventor
Life of this patent
Estimating the term…
Abstract
A system for producing a therapeutic oligomer includes a computing device configured to design a proposed therapeutic oligomer sequence, wherein designing further comprises generating a genomic library for an organism from a gene target, initiating a sequence identification function, identifying a genomic locus that the proposed therapeutic oligomer sequence is predicted to bond to as a function of an off-target sequence function, selecting the proposed therapeutic oligomer sequence as a function of the sequence identification function, the genomic locus, and a criterion element, and synthesize a therapeutic oligomer as a function of the proposed therapeutic oligomer sequence.
Claims24
A therapeutic oligomer composition, wherein the composition comprises:
- a therapeutic oligomer configured to regulate gene expression of a gene target within a target host, wherein the therapeutic oligomer comprises:
- at least a peptide nucleic acid (PNA) comprising at least a synthetic DNA-analog and 2-N-aminoethylglycine;
- a delivery nanoparticle comprising a Au22 to Au25 cluster and coated with glutathione;
- and
- a nanoparticle binding element comprising a 5-histidine sequence, wherein the nanoparticle binding element comprises a first end attached to the at least a PNA and a second end attached to the delivery nanoparticle to enable crossing of a blood-brain barrier.
Dependencies are inferred from the claim text.